Latest News from NPR

on:

NCPR is supported by:

 
Hourly Newscast
4 min., 45 sec.

Programs

Latest program rundown

Coming up:

Latest Features:
Basecamp Imaging/iStockphoto
July 30, 2014 | KQED · Adding a translation to the English label would require bigger bottles, pharmacists say. They worry patients would wind up carrying a few pills around loose — without any instructions at all.
 
WNYC
July 30, 2014 | WNYC · In the past 20 years, New Jersey went from having more than 20 percent of U.S. pharmaceutical manufacturing jobs to less than 10 percent. That means offices, labs and warehouses have gone dark.
 
July 30, 2014 | NPR · Sheik Humarr Khan, one of the doctors fighting to control West Africa's largest Ebola outbreak, died Tuesday in Sierra Leone. He was 39.
 

Latest program rundown

Coming up:

Latest Features:
July 30, 2014 | NPR · An explosion rocked a crowded Gaza market during what was expected to be a lull in the fighting. Earlier in the day a United Nations school was hit by what U.N. officials say was Israeli artillery fire, killing at least 15 people. Meanwhile, rocket fire from Gaza continues to be fired into Israel.
 
AP
July 30, 2014 | NPR · Hamas militants are using tunnels in and out of Gaza to strike inside Israel. Israelis are questioning how the tunnels grew to be so complex and why the military hasn't been able to shut them down.
 
Mike McCune/Flickr
July 30, 2014 | NPR · A food blogger says dozens of distilleries are buying rye whiskey from a factory in Indiana and using it in bottles labeled "artisan."
 

Latest Saturday rundown




WE Saturday Feature

July 26, 2014 | NPR · Hezbollah has been a longtime ally of Hamas, but during this most recent conflict between Israel and Gaza they've taken a sideline role. NPR's Scott Simon talks to the BBC's Kim Ghattas in Beirut.
 

Latest Sunday rundown


WE Sunday Feature

July 27, 2014 | NPR · Fighting in Ukraine near the crash site of Malaysia Airlines Flight MH17 has international investigators staying away. NPR's Arun Rath talks with OSCE's Michael Bociurkiw about the investigation.
 

Latest program rundown

Coming up:

Avastin

Apr 4, 2012 — U.S. medical practices bought counterfeit medicine labeled as Altuzan from a foreign supplier, the FDA says. Altuzan, which is the Turkish brand name for the blockbuster drug Avastin, is approved for use in Turkey but not in this country.
Comments |
Feb 15, 2012 — Counterfeit versions of diet drugs, Lipitor and a flu medication called Tamiflu have been found in this country before. But so far fake cancer medicines have been rare.
Comments |
Dec 29, 2011 — Avastin slowed the progression of the cancers a bit, but two studies didn't find the drug improved survival overall. Patients getting Avastin as part of treatment with several medicines had more side effects, including blood clots and high blood pressure, than the people who didn't get it.
Comments |
Nov 18, 2011 — After more than a year of deliberations and an unprecedented public hearing in June, the agency has revoked approval of the biotech blockbuster Avastin, a medicine that chokes off the blood supply to various cancer cells, as a treatment for metastatic breast cancer.
Comments |
Oct 13, 2011 — A cancer specialist on an expert panel that voted against keeping Avastin's approval for breast cancer intact explained his decision. He couldn't imagine recommending a drug that only limits progression of cancer without lengthening patient's lives or their quality of life.
Comments |
Jun 30, 2011 — The European Commission gave the OK to an expansion of Avastin's approval to include using the drug in combination with Xeloda, a chemotherapy medicine, to treat metastatic breast cancer.
Comments |
Jun 29, 2011 — Genentech failed to persuade a single member of the Food and Drug Administration's panel of cancer experts that its blockbuster drug Avastin should keep the agency's seal of approval for treating advanced breast cancer.
Comments |
Jun 29, 2011 — In a controversial 2008 decision, the FDA gave fast-track approval for Avastin for breast cancer treatment based on a single study. Now, after subsequent research proved disappointing, a panel has recommended that the agency revoke approval, angering patients and the drugmaker.
Comments |
Apr 29, 2011 — Medicare could save millions if patients with macular degeneration switch to a $50 cancer drug that's just as effective as a $2,000 drug approved for the eye disease. But it was a long haul to get the clinical trial done to prove it.
Comments |
more Avastin from NPR